vs

Side-by-side financial comparison of Clearfield, Inc. (CLFD) and Zymeworks Inc. (ZYME). Click either name above to swap in a different company.

Clearfield, Inc. is the larger business by last-quarter revenue ($34.3M vs $27.6M, roughly 1.2× Zymeworks Inc.). Clearfield, Inc. runs the higher net margin — -1.8% vs -71.0%, a 69.2% gap on every dollar of revenue. On growth, Zymeworks Inc. posted the faster year-over-year revenue change (72.6% vs -3.2%). Clearfield, Inc. produced more free cash flow last quarter ($-2.4M vs $-31.8M).

Clearfield, Inc. is a company headquartered in Minneapolis, Minnesota. The company produces fiber optic products.

Zymeworks Inc. is a publicly held biotechnology company based in Vancouver, British Columbia, that develops protein therapeutics for the treatment of cancer as well as for autoimmune and inflammatory diseases. The products are based upon the company's molecular modeling software for optimizing protein structure. In 2014, Zymeworks raised $44 million across various funding rounds according to PitchBook, placing it among the top 10 HealthTech businesses in the world to raise the most capital th...

CLFD vs ZYME — Head-to-Head

Bigger by revenue
CLFD
CLFD
1.2× larger
CLFD
$34.3M
$27.6M
ZYME
Growing faster (revenue YoY)
ZYME
ZYME
+75.8% gap
ZYME
72.6%
-3.2%
CLFD
Higher net margin
CLFD
CLFD
69.2% more per $
CLFD
-1.8%
-71.0%
ZYME
More free cash flow
CLFD
CLFD
$29.4M more FCF
CLFD
$-2.4M
$-31.8M
ZYME

Income Statement — Q1 FY2026 vs Q3 FY2025

Metric
CLFD
CLFD
ZYME
ZYME
Revenue
$34.3M
$27.6M
Net Profit
$-614.0K
$-19.6M
Gross Margin
33.2%
Operating Margin
-5.3%
-80.1%
Net Margin
-1.8%
-71.0%
Revenue YoY
-3.2%
72.6%
Net Profit YoY
67.8%
34.3%
EPS (diluted)
$-0.04
$-0.26

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLFD
CLFD
ZYME
ZYME
Q4 25
$34.3M
Q3 25
$23.4M
$27.6M
Q2 25
$49.9M
$48.7M
Q1 25
$47.2M
$27.1M
Q4 24
$29.7M
$31.0M
Q3 24
$5.6M
$16.0M
Q2 24
$48.8M
$19.2M
Q1 24
$36.9M
$10.0M
Net Profit
CLFD
CLFD
ZYME
ZYME
Q4 25
$-614.0K
Q3 25
$-9.1M
$-19.6M
Q2 25
$1.6M
$2.3M
Q1 25
$1.3M
$-22.6M
Q4 24
$-1.9M
$-23.5M
Q3 24
$-29.9M
Q2 24
$-447.0K
$-37.7M
Q1 24
$-5.9M
$-31.7M
Gross Margin
CLFD
CLFD
ZYME
ZYME
Q4 25
33.2%
Q3 25
53.2%
Q2 25
30.5%
Q1 25
30.1%
Q4 24
29.2%
Q3 24
Q2 24
21.9%
Q1 24
7.7%
Operating Margin
CLFD
CLFD
ZYME
ZYME
Q4 25
-5.3%
Q3 25
10.3%
-80.1%
Q2 25
3.0%
-1.4%
Q1 25
0.6%
-94.5%
Q4 24
-6.9%
-71.6%
Q3 24
-213.8%
Q2 24
-4.7%
-222.9%
Q1 24
-26.4%
-376.9%
Net Margin
CLFD
CLFD
ZYME
ZYME
Q4 25
-1.8%
Q3 25
-38.8%
-71.0%
Q2 25
3.2%
4.8%
Q1 25
2.8%
-83.5%
Q4 24
-6.4%
-75.8%
Q3 24
-186.6%
Q2 24
-0.9%
-195.8%
Q1 24
-16.0%
-315.6%
EPS (diluted)
CLFD
CLFD
ZYME
ZYME
Q4 25
$-0.04
Q3 25
$-0.65
$-0.26
Q2 25
$0.11
$0.03
Q1 25
$0.09
$-0.30
Q4 24
$-0.13
$-0.32
Q3 24
$-0.39
Q2 24
$-0.04
$-0.49
Q1 24
$-0.40
$-0.42

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLFD
CLFD
ZYME
ZYME
Cash + ST InvestmentsLiquidity on hand
$96.4M
$64.8M
Total DebtLower is stronger
Stockholders' EquityBook value
$249.7M
$320.1M
Total Assets
$268.1M
$397.3M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLFD
CLFD
ZYME
ZYME
Q4 25
$96.4M
Q3 25
$106.0M
$64.8M
Q2 25
$117.2M
$98.3M
Q1 25
$112.0M
$76.2M
Q4 24
$113.0M
$66.1M
Q3 24
$129.0M
$122.4M
Q2 24
$123.8M
$71.0M
Q1 24
$142.9M
$114.8M
Total Debt
CLFD
CLFD
ZYME
ZYME
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$2.2M
Q2 24
$2.1M
Q1 24
Stockholders' Equity
CLFD
CLFD
ZYME
ZYME
Q4 25
$249.7M
Q3 25
$256.2M
$320.1M
Q2 25
$264.5M
$334.5M
Q1 25
$265.9M
$325.0M
Q4 24
$267.4M
$338.8M
Q3 24
$275.8M
$367.0M
Q2 24
$274.6M
$406.2M
Q1 24
$279.2M
$438.0M
Total Assets
CLFD
CLFD
ZYME
ZYME
Q4 25
$268.1M
Q3 25
$306.2M
$397.3M
Q2 25
$314.7M
$408.4M
Q1 25
$310.9M
$425.5M
Q4 24
$303.2M
$463.1M
Q3 24
$315.3M
$487.2M
Q2 24
$318.1M
$515.6M
Q1 24
$315.4M
$553.8M
Debt / Equity
CLFD
CLFD
ZYME
ZYME
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.01×
Q2 24
0.01×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLFD
CLFD
ZYME
ZYME
Operating Cash FlowLast quarter
$-1.4M
$-31.4M
Free Cash FlowOCF − Capex
$-2.4M
$-31.8M
FCF MarginFCF / Revenue
-7.1%
-115.2%
Capex IntensityCapex / Revenue
2.9%
1.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-65.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLFD
CLFD
ZYME
ZYME
Q4 25
$-1.4M
Q3 25
$-31.4M
Q2 25
$7.9M
$12.1M
Q1 25
$3.0M
$-3.4M
Q4 24
$7.2M
$-41.5M
Q3 24
$22.2M
$-5.9M
Q2 24
$4.0M
$-25.0M
Q1 24
$-5.7M
$-37.7M
Free Cash Flow
CLFD
CLFD
ZYME
ZYME
Q4 25
$-2.4M
Q3 25
$-31.8M
Q2 25
$7.5M
$11.6M
Q1 25
$654.0K
$-3.4M
Q4 24
$5.1M
$-41.8M
Q3 24
$18.2M
$-6.8M
Q2 24
$2.8M
$-25.6M
Q1 24
$-7.7M
$-37.9M
FCF Margin
CLFD
CLFD
ZYME
ZYME
Q4 25
-7.1%
Q3 25
-115.2%
Q2 25
15.1%
23.7%
Q1 25
1.4%
-12.6%
Q4 24
17.1%
-134.8%
Q3 24
323.0%
-42.4%
Q2 24
5.8%
-133.0%
Q1 24
-20.8%
-377.5%
Capex Intensity
CLFD
CLFD
ZYME
ZYME
Q4 25
2.9%
Q3 25
2.0%
1.5%
Q2 25
0.8%
1.1%
Q1 25
5.1%
0.1%
Q4 24
7.0%
1.0%
Q3 24
71.4%
5.6%
Q2 24
2.5%
3.1%
Q1 24
5.3%
1.8%
Cash Conversion
CLFD
CLFD
ZYME
ZYME
Q4 25
Q3 25
Q2 25
4.93×
5.21×
Q1 25
2.30×
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons